X4 Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for X4 Pharmaceuticals (XFOR).

Price Target Range — 11 Quarters

Analyst Consensus — 7 Analysts

6Buy

1Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$13Upside to Avg. PT+282.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 10, 2026	Wells Fargo	Derek Archila	Initiate	Overweight	$11
Jun 2, 2026	Leerink Partners	Thomas Smith	Initiate	Outperform	$12
Mar 9, 2026	Guggenheim	Michael Schmidt	Initiate	Buy	$12
Dec 5, 2025	Stifel	James Condulis	PT Raise	Buy	$8→$10
Nov 10, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$4→$5
Aug 29, 2025	Stifel	Stephen Willey	PT Cut	Buy	$30→$9
Aug 13, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$7→$4
May 2, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$2→$7
Mar 27, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$45
Mar 26, 2025	Cantor Fitzgerald	Kristen Kluska	Maintained	Overweight	$90
Feb 7, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$45
Jan 14, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$45
Nov 14, 2024	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$150→$45
Nov 14, 2024	Stifel	Stephen Willey	PT Cut	Buy	$150→$120
Jun 28, 2024	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$150
May 31, 2024	Cantor Fitzgerald	Kristen Kluska	Maintained	Overweight	$150
Apr 30, 2024	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$90→$150
Mar 22, 2024	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$90
Dec 12, 2023	B. Riley Securities	Kalpit Patel	Downgrade	Buy→Neutral	$90→$30

Analyst Ratings News

PRO
Wells Fargo Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $11

Wells Fargo analyst Derek Archila initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Overweight rating and announces Price Target of $11.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On X4 Pharmaceuticals with Outperform Rating, Announces Price Target of $12

Leerink Partners analyst Thomas Smith initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Outperform rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On X4 Pharmaceuticals with Buy Rating, Announces Price Target of $12

Guggenheim analyst Michael Schmidt initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
Stifel Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $10

Stifel analyst James Condulis maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $7.5 to $10.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $3.5 to $5.

Benzinga Newsdesk

PRO
Stifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $9

Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $30 to $9.

Benzinga Newsdesk

X4 Pharmaceuticals Inc

X4 Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wells Fargo Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $11

PRO
Leerink Partners Initiates Coverage On X4 Pharmaceuticals with Outperform Rating, Announces Price Target of $12

PRO
Guggenheim Initiates Coverage On X4 Pharmaceuticals with Buy Rating, Announces Price Target of $12

PRO
Stifel Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $10

PRO
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5

PRO
Stifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $9

People Also Watch

People Also Watch

X4 Pharmaceuticals Inc

X4 Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWells Fargo Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $11

PROLeerink Partners Initiates Coverage On X4 Pharmaceuticals with Outperform Rating, Announces Price Target of $12

PROGuggenheim Initiates Coverage On X4 Pharmaceuticals with Buy Rating, Announces Price Target of $12

PROStifel Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $10

PROHC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5

PROStifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $9

People Also Watch

People Also Watch

PRO
Wells Fargo Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $11

PRO
Leerink Partners Initiates Coverage On X4 Pharmaceuticals with Outperform Rating, Announces Price Target of $12

PRO
Guggenheim Initiates Coverage On X4 Pharmaceuticals with Buy Rating, Announces Price Target of $12

PRO
Stifel Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $10

PRO
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5

PRO
Stifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $9